Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
NCT06832839, Recruiting, Beijing Tiantan Hospital
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease | ClinicalTrials.gov |
| NCT number | NCT06832839 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Enrollment | 360 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Beijing Tiantan Hospital | ClinicalTrials.gov |
| Conditions | Moyamoya Disease | ClinicalTrials.gov |
| Interventions | Revascularization | ClinicalTrials.gov |
| First posted | 2025-02-18 | ClinicalTrials.gov |
| Last updated | 2025-02-18 | ClinicalTrials.gov |
Registered outcomes 15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in composite score of neurocognitive function at 6 months after treatment. | 6 months during follow-up | The composite score of neurocognitive function, including Weschsler Adult Intelligence Scale-4th Edition (WAIS-IV), MATRICS Consensus Cognitive Battery (MCCB), Montreal Cognitive Assessment (MoCA), Auditory Verbal Learning Test (AVLT), Rey-Osterrieth complex figure (ROCF), Trail Making Test (TMT), Stroop test, Verbal Fluency Test (VFT), and Boston Naming Test (BNT) will be collected before and 6 months after treatment. | ClinicalTrials.gov |
| Secondary | Changes in composite score of neurocognitive function at 12 and 24 months after treatment. | 12 and 24 months during follow-up | The composite score of neurocognitive function, including Weschsler Adult Intelligence Scale-4th Edition (WAIS-IV), MATRICS Consensus Cognitive Battery (MCCB), Montreal Cognitive Assessment (MoCA), Auditory Verbal Learning Test (AVLT), Rey-Osterrieth complex figure (ROCF), Trail Making Test (TMT), Stroop test, Verbal Fluency Test (VFT), and Boston Naming Test (BNT) will be collected before and 12 and 24 months after treatment. | ClinicalTrials.gov |
| Secondary | Rate of participants experiencing cerebrovascular events (TIA, infarction and hemorrhage) within 6, 12 and 24 months after treatment. | 6, 12 and 24 months during follow-up | ClinicalTrials.gov | |
| Secondary | Changes in neurological function assessed by modified Rankin scale (mRS) at 6, 12, and 24 months following treatment. | 6, 12 and 24 months during follow-up | ClinicalTrials.gov | |
| Secondary | Changes in neurological function assessed by National Institute of Health stroke scale (NIHSS) at 6, 12, and 24 months following treatment. | 6, 12 and 24 months during follow-up | ClinicalTrials.gov | |
| Secondary | Changes in cerebral blood perfusion assessed by arterial spin labeling (ASL) at 6, 12, and 24 months after treatment. | 6, 12 and 24 months during follow-up | ClinicalTrials.gov | |
| Secondary | Hemodynamic changes at the terminal segment of internal carotid artery assessed by computational fluid dynamics (CFD) at 6, 12, and 24 months after treatment. | 6, 12 and 24 months during follow-up | ClinicalTrials.gov | |
| Secondary | Morphological changes at the terminal segment of internal carotid artery and middle cerebral artery wall assessed by high-resolution vessel wall imaging at 6, 12, and 24 months after treatment. | 6, 12 and 24 months during follow-up | ClinicalTrials.gov | |
| Secondary | Changes in Power Spectral Density (PSD) assessed by electroencephalography (EEG) at 6, 12, and 24 months after treatment will be measured. | 6, 12 and 24 months during follow-up | ClinicalTrials.gov | |
| Secondary | Changes in Phase Locking Value (PLV) assessed by electroencephalogram (EEG) at 6, 12, and 24 months after treatment will be measured. | 6, 12 and 24 months during follow-up | ClinicalTrials.gov | |
| Secondary | Changes in Phase-Lag Index (PLI) assessed by electroencephalogram (EEG) at 6, 12, and 24 months after treatment will be measured. | 6, 12 and 24 months during follow-up | ClinicalTrials.gov | |
| Secondary | Changes in Degree Centrality assessed by multimodal MRI at 6, 12, and 24 months after treatment. | 6, 12 and 24 months during follow-up | ClinicalTrials.gov | |
| Secondary | Changes in Clustering Coefficient assessed by multimodal MRI at 6, 12, and 24 months after treatment. | 6, 12 and 24 months during follow-up | ClinicalTrials.gov | |
| Secondary | Changes in Structural Connectivity Strength assessed by multimodal MRI at 6, 12, and 24 months after treatment. | 6, 12 and 24 months during follow-up | ClinicalTrials.gov | |
| Secondary | Changes in Network Density assessed by multimodal MRI at 6, 12, and 24 months after treatment. | 6, 12 and 24 months during follow-up | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 7
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Complex Figure Copy and Recall | Primary outcome | ConductCognition |
| Picture Naming Test | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Verbal Fluency | Primary outcome | ConductCognition |
| Verbal Learning | Primary outcome | ConductCognition |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.3.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 4a570df2e7274cee2d4fa2959402fab41880e2cd412e4b590390035fbea69391 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
Release trials-2026-11-12-0.3.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.